预测阿尔茨海默病和轻度认知障碍的认知和功能衰退率

相关实验视频

Updated: Feb 28, 2026

12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K

Antigone Fogel^1,2, Chloe Walsh^3,4,5, Nan Fletcher-Lloyd^3,4

¹Department of Brain Sciences, Imperial College London, London, UK. antigone.fogel23@imperial.ac.uk.

Communications medicine

|February 26, 2026

概括

机器学习模型使用可访问的临床数据预测痴呆症的认知和功能衰退. 这些工具为患有痴呆症的人 (PLWD) 提供可扩展,个性化的预后,改善家庭的护理规划和清晰度.

科学领域:

神经科学和人工智能人工智能
老年学与公共卫生

背景情况:

全球痴呆症患病率不断上升,需要改进预后工具.
目前的痴呆症进展模型缺乏可扩展性,并依赖于无法访问的数据.
痴呆症轨迹的异质性没有得到现有指导方针的充分体现.

研究的目的:

开发可扩展的机器学习模型,用于预测阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的认知和功能衰退.
利用常规收集的临床数据来获得可访问的痴呆症预后.
支持为痴呆症患者 (PLWD) 提供个性化护理计划.

主要方法:

在三年内在153个临床轨迹上训练了两个机器学习算法.
预计12个月的认知能力下降 (迷你精神状态检查 - MMSE) 和功能下降 (Bristol日常生活活动 - BADL).
在ADNI队列中的741个轨迹上进行了外部验证的模型.

主要成果:

MMSE模型实现了1.84 (内部) 和2.19 (外部验证) 的平均绝对误差 (MAE).
在BADL模型中,MAE达到3.88.
关键预测因素包括基线思想实践,定向,认知的单词回忆,以及在准备食物,财务和穿着功能方面的独立性.

结论:

模型利用易于访问,常规收集的数据,显示出高的翻译潜力.
可扩展,数据驱动的预后工具可以简化临床工作流程.
这些工具为PLWD及其家人提供了更好的清晰度和保证.

相关概念视频

01:26

Alzheimer's Disease: Overview

1.9K

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

1.9K

01:30

Cognitive Development During Adulthood

988

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...

988

01:22

Alzheimer's Disease: Treatment

1.1K

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

1.1K

01:30

Dementia

609

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

609

01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

735

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

735

预测阿尔茨海默病和轻度认知障碍的认知和功能衰退率

相关实验视频

科学领域:

背景情况:

研究的目的:

主要方法:

主要成果:

结论:

更多相关视频

相关概念视频